Table 1 Distribution of characteristics according to amyloid status in the development (N = 1505) and external validation (N = 260) samples
Development set: MEMENTO | Validation set: ADC | |||||
|---|---|---|---|---|---|---|
Aβ – | Aβ + | Total | Aβ – | Aβ + | Total | |
N (%) | 1090 (72.4) | 415 (27.6) | 1505 | 132 (50.8) | 128 (49.2) | 260 |
Characteristics at amyloid assessment: | ||||||
Demographics | ||||||
Sex female - n (%) | 629 (57.7) | 230 (55.4) | 859 (57.1) | 37 (28.0) | 61 (47.7) | 98 (37.7) |
Age (years) - median [Q1-Q3] | 73.3 [67.9–77.6] | 76,5 [72,1–80,1] | 74,3 [68,8–78,3] | 66.5 [63.2–70.0] | 68.7 [65.5–71.4] | 67.6 [63.9–71.2] |
High educational level* - n (%) | 520 (47.8) | 172 (41.4) | 692 (46.0) | 35 (26.5) | 31 (24.2) | 66 (25.4) |
Family history of AD - n (%) | 346 (31.9) | 143 (34.6) | 489 (32.7) | 58 (43.9) | 83 (64.8) | 141 (54.2) |
BMI < 25 kg/m²- n (%) | 517 (47.4) | 220 (53.0) | 737 (49.0) | 50 (37.9) | 72 (56.2) | 122 (46.9) |
Cognition | ||||||
Memory testa (number of words) - median [Q1-Q3]: | ||||||
FCSRT – Free recall | 31 [26–35] | 26 [17–32] | 30 [24–34] | - | - | - |
RAVLT – Free recall | - | - | - | 20 [15–25] | 20 [15–25] | 20 [15–25] |
TMT B (time in seconds) - median [Q1-Q3] | 84 [65–110] | 105 [79–152] | 89 [67–117] | 90.0 [71.8-123.2] | 104.0 [78.8-138.8] | 95.5 [75-131.2] |
Verbal fluency (animals)b (number of words) - median [Q1-Q3]: | ||||||
Conducted in 2 min | 30 [24–36] | 28 [21–34] | 29 [23–35] | - | - | - |
Conducted in 1 min | - | - | - | 20 [17-24.2] | 19 [16–23] | 12 [16–24] |
MMSE (total score) - median [Q1-Q3] | 29 [28–30] | 28 [26–29] | 29 [27–30] | 28 [27–29] | 27 [26–29] | 28 [26–29] |
CDR = 0 - n (%) | 660 (61.7) | 194 (48.1) | 854 (58.0) | 73 (55.3) | 39 (30.5) | 112 (43.1) |
CDR = 0.5 - n (%) | 409 (38.3) | 209 (51.9) | 618 (42.0) | 59 (44.7) | 89 (69.5) | 148 (56.9) |
Genetic | ||||||
Presence of ApoE ε4 alleles - n (%) | ||||||
No ε4 allele | 799 (76.6) | 189 (47.1) | 988 (68.4) | 105 (79.5) | 28 (21.9) | 133 (51.2) |
1 ε4 allele | 229 (22.0) | 182 (45.4) | 411 (28.5) | 26 (19.7) | 65 (50.8) | 91 (35.0) |
2 ε4 alleles | 15 (1.4) | 30 (7.5) | 45 (3.1) | 1 (0.8) | 35 (27.3) | 36 (13.8) |
Blood | ||||||
AB42/40 ratio - median [Q1-Q3] | 0.06 [0.05–0.07] | 0.05 [0.04–0.06] | 0.06 [0.05–0.06] | 0.06 [0.05–0.06] | 0.05 [0.05–0.06] | 0.05 [0.05–0.06] |
Ptau181 - median [Q1-Q3] | 0.70 [0.48–0.98] | 1.20 [0.82–1.75] | 0.79 [0.51–1.21] | 1.4 [1.1–1.7] | 2.1 [1.7–2.6] | 1.7 [1.3–2.3] |
MRI | ||||||
Hippocampal atrophy | ||||||
No atrophy - n (%) | 106 (9.8) | 21 (5.1) | 127 (8.5) | 44 (33.3) | 39 (30.5) | 83 (31.9) |
Possible atrophy - n (%) | 729 (67.6) | 208 (50.5) | 937 (62.9) | 64 (48.5) | 56 (43.8) | 120 (46.2) |
Discrete atrophy - n (%) | 175 (16.2) | 109 (26.5) | 284 (19.1) | 22 (16.7) | 28 (21.9) | 50 (19.2) |
Moderate atrophy - n (%) | 55 (5.1) | 62 (15.0) | 117 (7.9) | 2 (1.5) | 5 (3.9) | 7 (2.7) |
Severe atrophy- n (%) | 13 (1.2) | 12 (2.9) | 25 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Lobar microbleedsc - median [min - max] | 0 [0–50] | 0 [0–25] | 0 [0–50] | 0 [0–20] | 0 [0-100] | 0 [0-100] |